|
|
cancer associated thrombosis in everyday practice: perspectives from garfield-vte
|
|
|
|
|
نویسنده
|
weitz jeffrey i. ,haas sylvia ,ageno walter ,goldhaber samuel z. ,turpie alexander g. g. ,goto shinya ,angchaisuksiri pantep ,nielsen jørn dalsgaard ,kayani gloria ,farjat alfredo e. ,schellong sebastian ,bounameaux henri ,mantovani lorenzo g. ,prandoni paolo ,kakkar ajay k. ,investigators the garfield-vte
|
منبع
|
journal of thrombosis and thrombolysis - 2020 - دوره : 50 - شماره : 2 - صفحه:267 -277
|
چکیده
|
Venous thromboembolism (vte) is common in cancer patients and is an important cause of morbidity and mortality. the global anticoagulant registry in the field (garfield)–vte (clinicaltrials.gov: nct02155491) is a prospective, observational study of 10,684 patients with objectively diagnosed vte from 415 sites in 28 countries. we compared baseline characteristics, vte treatment patterns, and 1-year outcomes (mortality, recurrent vte and major bleeding) in 1075 patients with active cancer, 674 patients with a history of cancer, and 8935 patients without cancer. patients with active cancer and history of cancer were older than cancer-free patients, with median ages of 64.8, 68.9, and 58.4 years, respectively. the most common sites of active cancer were lung (14.5%), colorectal (11.0%), breast (10.6%), and gynaecological (10.3%). active cancer patients had a higher incidence of upper limb and vena cava thrombosis than cancer-free patients (9.0% vs 4.8% and 5.1% vs 1.4%, respectively), and were more likely to receive parenteral anticoagulation as monotherapy than cancer-free patients (57.8% vs 12.1%), and less likely to receive doacs (14.2% vs 50.6%). rates of death, recurrent vte, and major bleeding were higher in active cancer patients than in cancer-free patients, with hazard ratios (95% confidence intervals) of 14.2 (12.1–16.6), 1.6 (1.2–2.0) and 3.8 (2.9–5.0), respectively. vte was the second most common cause of death in patients with active cancer or history of cancer. in patients with vte, those with active cancer are at higher risk of death, recurrence, and major bleeding than those without cancer.
|
کلیدواژه
|
cancer ,malignancy ,venous thromboembolism ,anticoagulation ,registry
|
آدرس
|
mcmaster university, thrombosis and atherosclerosis research institute, canada, technical university of munich, germany, university of insubria, department of medicine and surgery, italy, brigham and women’s hospital and harvard medical school, usa, mcmaster university, canada, tokai university school of medicine, department of medicine (cardiology), japan, mahidol university, ramathibodi hospital, department of medicine, thailand, copenhagen university hospital, denmark, thrombosis research institute, uk, thrombosis research institute, uk, municipal hospital dresden, medical department 2, germany, university hospital of geneva, faculty of medicine, switzerland, irccs multimedica, italy. university of milano-bicocca, italy, arianna foundation on anticoagulation, italy, thrombosis research institute, uk. university college london, uk
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Authors
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|